Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer
By: prepared for Agency for Health Care Policy and Research ; prepared by Blue Cross and Blue Shield Association ; Naomi Aronson, program director ... [et al.].
Contributors: Aronson, Naomi.; United States. Agency for Health Care Policy and Research.; Blue Cross and Blue Shield Association.
Series: Evidence report/technology assessment -- no. 4.; AHCPR publication -- no. 99-E0012.; AHCPR pub -- no. 99-E 0012.
Publisher: The Agency
Published: 1999
Place of publication: Rockville, Md
Language: eng
Subjects: Prostate -- Cancer -- Hormone therapy.; Antiandrogens -- Therapeutic use.; Prostatic Neoplasms -- drug therapy.; Antineoplastic Agents, Hormonal -- therapeutic use.; Cost-Benefit Analysis.; Gonadorelin -- agonists.; Treatment Outcome.
Other titles: Relative effectiveness and cost effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Notes: Not distributed to depository libraries in a physical form.

"May 1999."

"Contract no. 290-97-0015."

Includes bibliographical references.

Available via Internet from the National Library of Medicine web site. Address as of 10/2/01: http://hstat.nlm.nih.gov/ftrs/pick?collect=epc&dbName=prost&cd=1&t=1002035486; current access is available via PURL.